Linezolid Treatment for Gram-Positive Infections: A Retrospective Comparison with Teicoplanin
Authors:
- C. TasciniCTC. Tascini
- G. GemignaniGGG. Gemignani
- R. DoriaRDR. Doria
- G. BiancofioreGBG. Biancofiore
- L. UrbaniLUL. Urbani
- C. MoscaCMC. Mosca
- P. MalacarnePMP. Malacarne
- F. PapineschiFPF. Papineschi
- C. PassagliaCPC. Passaglia
- L. Dal CantoLCL. Dal Canto
- M. ProcacciniMPM. Procaccini
- G. FurneriGFG. Furneri
- 1 June 2009
- journal article
- research article
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 21 (3) , 311-316
Abstract
In randomized studies linezolid, indicated for Gram-positive infections, was as effective as teicoplanin in critical ill patients or was superior to teicoplanin in skin infection, pneumonia and bacteremia. We performed a 2-year comparative, retrospective study of patients treated with linezolid or teicoplanin in a single hospital for the same indications. We collected information about the type of infection, the responsible pathogen, therapy administered before study drugs, antibiotic associated with the study drugs, length of hospital stay (LOS), adverse events and outcome of the infections. The aim of the study was to evaluate the efficacy of linezolid in this retrospective patients series. Overall we identified 169 patients treated with linezolid and 91 with teicoplanin. Response to therapy, (resolution or improvement of infection) was better in patients treated with linezolid compared to teicoplanin (83.9% versus 69.2%, p=0.002). Response to therapy by type of pathogen showed the superior efficacy of linezolid against Staphylococcus aureus (including MRSA) and enterococci; although not statistically significant because of the small number of patients enrolled, they were close to significance (p<0.056 for S. aureus, p<0.055 for MRSA, p<0.061 for enterococci). Overall LOS in linezolid-treated patients was 4.6 days (p<0.041) less. Empirical use of linezolid reduced lOS by 6 days (p<0.038), especially in VAP and bacteremia patients (p<0.05). Mortality due to infection was 9.8% in both groups, and adverse events were most frequently documented in linezolid-treated patients. Linezolid was clinically superior to teicoplanin in the treatment of Gram-positive infections.Keywords
This publication has 10 references indexed in Scilit:
- Linezolid versus glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trialsThe Lancet Infectious Diseases, 2008
- Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue InfectionsAntimicrobial Agents and Chemotherapy, 2005
- Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureusThe American Journal of Surgery, 2005
- Healthcare-associated pneumonia in adults: management principles to improve outcomesInfectious Disease Clinics of North America, 2004
- An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effectsInternational Journal of Antimicrobial Agents, 2004
- A review of linezolid: the first oxazolidinone antibioticExpert Review of Anti-infective Therapy, 2004
- Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infectionsJournal of Antimicrobial Chemotherapy, 2004
- Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycinIntensive Care Medicine, 2004
- Quinupristin‐Dalfopristin and Linezolid: Evidence and OpinionClinical Infectious Diseases, 2003
- Linezolid: The First Oxazolidinone AntimicrobialAnnals of Internal Medicine, 2003